{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:57:51Z","timestamp":1790546271214,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e36512","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:35:41Z","timestamp":1725028541000},"page":"e36512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Regulatory T lymphocytes as a treatment method for rheumatoid arthritis \u2013 Superiority of allogeneic to autologous cells"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0484-8671","authenticated-orcid":false,"given":"Joanna","family":"Chmiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Stasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Skrzypkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucjan","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"\u0141uczkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Trzonkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.dhjo.2017.04.010","article-title":"Prevalence and causes of work disability among working-age U.S. adults, 2011-2013, NHIS","volume":"11","author":"Theis","year":"2018","journal-title":"Disabil Health J"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36512_bib4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e36512_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108793","article-title":"Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis","volume":"230","author":"Liu","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.heliyon.2024.e36512_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108680","article-title":"Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis","volume":"225","author":"Koga","year":"2021","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.heliyon.2024.e36512_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3389\/fimmu.2019.00680","article-title":"The pivotal role of regulatory T cells in the regulation of innate immune cells","volume":"10","author":"Okeke","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib11","first-page":"385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e36512_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109716","article-title":"Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: progress in type 1 diabetes","volume":"255","author":"Bi","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.heliyon.2024.e36512_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109806","article-title":"T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity","volume":"256","author":"Esparcia-Pinedo","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.heliyon.2024.e36512_bib14","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3389\/fimmu.2019.03100","article-title":"Treg heterogeneity, function, and homeostasis","volume":"10","author":"Shevyrev","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib15","article-title":"Regulatory T cell function in autoimmune disease","volume":"4","author":"Rajendeeran","year":"2021","journal-title":"J Transl Autoimmun"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00281-019-00741-8","article-title":"Treg cells in autoimmunity: from identification to Treg-based therapies","volume":"41","author":"G\u00f6schl","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"119","key":"10.1016\/j.heliyon.2024.e36512_bib17","first-page":"73","article-title":"Regulatory T cell-based therapies for autoimmunity","volume":"22","author":"Arellano","year":"2016","journal-title":"Discov. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2024.e36512_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/JIR.S286426","article-title":"The role of regulatory B cells in health and diseases: a systemic review","volume":"14","author":"Chekol Abebe","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.heliyon.2024.e36512_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.imlet.2022.05.004","article-title":"A fresh look at a neglected regulatory lineage: CD8+Foxp3+ Regulatory T cells","volume":"247","author":"Liston","year":"2022","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.heliyon.2024.e36512_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fimmu.2018.00339","article-title":"Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes","volume":"9","author":"Moro-Garc\u00eda","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e36512_bib25","doi-asserted-by":"crossref","first-page":"11056","DOI":"10.1111\/jcmm.15743","article-title":"Molecular mechanism for impaired suppressive function of Tregs in autoimmune diseases: a summary of cell-intrinsic and cell-extrinsic factors","volume":"24","author":"Yang","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib26","first-page":"2443","article-title":"Stability and inhibitory function of Treg cells under inflammatory conditions in vitro","volume":"18","author":"Guo","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.heliyon.2024.e36512_bib27","article-title":"Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jaci.2018.11.047","article-title":"IL-21 promotes allergic airway inflammation by driving apoptosis of FoxP3+ regulatory T cells","volume":"143","author":"Tortola","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-\u03b1 in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.heliyon.2024.e36512_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196931","article-title":"Targeting transcription factors for therapeutic benefit in rheumatoid arthritis","volume":"14","author":"Balendran","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e36512_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1122063","article-title":"T regulatory cells metabolism: the influence on functional properties and treatment potential","volume":"14","author":"Tomaszewicz","year":"2023","journal-title":"Front. Immunol."},{"issue":"51","key":"10.1016\/j.heliyon.2024.e36512_bib34","doi-asserted-by":"crossref","first-page":"25790","DOI":"10.1073\/pnas.1907224116","article-title":"Homeobox protein Hhex negatively regulates Treg cells by inhibiting Foxp3 expression and function","volume":"116","author":"Jang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36512_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121887","article-title":"The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine-induced ER stress response","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2024.e36512_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.626172","article-title":"Post-Translational regulations of Foxp3 in Treg cells and their therapeutic applications","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib37","article-title":"The effects of post-translational modifications on Th17\/Treg cell differentiation","volume":"1869","author":"Le","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41413-023-00244-1","article-title":"Comprehensive overview of microRNA function in rheumatoid arthritis","volume":"11","author":"Peng","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.heliyon.2024.e36512_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3232061","article-title":"The role of MicroRNAs in regulatory T cells","volume":"2020","author":"Liu","year":"2020","journal-title":"J Immunol Res"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e36512_bib40","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/cells12131749","article-title":"Role of miRNAs in rheumatoid arthritis therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e36512_bib41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3389\/fimmu.2019.01311","article-title":"Protease activated receptor 4 as a novel modulator of regulatory T cell function","volume":"10","author":"Peng","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1301060","article-title":"Mst1\/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1\/Foxo3 stability in autoimmune disease","volume":"192","author":"Du","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2013.49","article-title":"The fate of regulatory T cells: survival or apoptosis","volume":"11","author":"Shen","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41590-021-01001-4","article-title":"Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity","volume":"22","author":"Hu","year":"2021","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coi.2010.08.012","article-title":"Human regulatory T cells in autoimmune diseases","volume":"22","author":"Cvetanovich","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"10391","key":"10.1016\/j.heliyon.2024.e36512_bib46","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib47","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00018-022-04563-0","article-title":"Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential","volume":"79","author":"Yan","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36512_bib49","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/art.20499","article-title":"CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid","volume":"50","author":"van Amelsfort","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36512_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162306","article-title":"The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis","volume":"11","author":"Morita","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-\u03b1 in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00296-022-05103-6","article-title":"Cytokines and chemokines multiplex analysis in patients with low disease activity rheumatoid arthritis","volume":"42","author":"Skrzypkowska","year":"2022","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.heliyon.2024.e36512_bib54","article-title":"Function and role of regulatory T cells in rheumatoid arthritis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/art.22414","article-title":"Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis","volume":"56","author":"van Amelsfort","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e36512_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109814","article-title":"Negative impact of Interleukin-9 on synovial regulatory T cells in rheumatoid arthritis","volume":"257","author":"Chakraborty","year":"2023","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib57","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory T cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib58","first-page":"356","article-title":"T cells in osteoarthritis: alterations and beyond","volume":"8","author":"Li","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/ar4545","article-title":"CD4\u207aCD25\u207a\/highCD127low\/\u207b regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints--analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood","volume":"16","author":"Moradi","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e36512_bib60","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1161\/CIRCULATIONAHA.120.046789","article-title":"A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction","volume":"142","author":"Xia","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-021-00641-4","article-title":"Regulatory T cells in ischemic stroke","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36512_bib62","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.immuni.2021.04.022","article-title":"Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke","volume":"54","author":"Shi","year":"2021","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20590","article-title":"Incompetent memory immune response in severe COVID-19 patients under treatment","volume":"9","author":"Das","year":"2023","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36512_bib64","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib65","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.2147\/CMAR.S228887","article-title":"T-regulatory cells in tumor progression and therapy","volume":"11","author":"Verma","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36512_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10450","article-title":"Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics","volume":"8","author":"Dwivedi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e36512_bib67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40259-017-0228-3","article-title":"Cell-based therapies with T regulatory cells","volume":"31","author":"Gliwi\u0144ski","year":"2017","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/eji.201948131","article-title":"Treg cell therapy: how cell heterogeneity can make the difference","volume":"51","author":"Giganti","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101740","article-title":"Protocol for in vitro isolation, induction, expansion, and determination of human natural regulatory T cells and induced regulatory T cells","volume":"3","author":"Gu","year":"2022","journal-title":"STAR Protoc"},{"issue":"304","key":"10.1016\/j.heliyon.2024.e36512_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7721","article-title":"Hurdles in therapy with regulatory T cells","volume":"7","author":"Trzonkowski","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e36512_bib72","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2017.01844","article-title":"Minimum information about T regulatory cells: a step toward reproducibility and standardization","volume":"8","author":"Fuchs","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109328","article-title":"Manufacturing regulatory T cells for adoptive cell therapy in immune diseases: a critical appraisal","volume":"251","author":"Abhishek","year":"2023","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imm.13460","article-title":"Distinguishing activated T regulatory cell and T conventional cells by single-cell technologies","volume":"166","author":"Reinhardt","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2024.e36512_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744763","article-title":"Polyclonal regulatory T cell manufacturing under cGMP: a decade of experience","volume":"12","author":"Balcerek","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783282","article-title":"IL-6 and TNF\u03b1 drive extensive proliferation of human Tregs without compromising their lineage stability or function","volume":"12","author":"Skartsis","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36512_bib77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/intimm\/dxx049","article-title":"Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation","volume":"29","author":"Someya","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41423-022-00869-y","article-title":"Retinoic acid signaling acts as a rheostat to balance Treg function","volume":"19","author":"Thangavelu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.trsl.2017.06.009","article-title":"Antigen-specific regulatory T cells: are police CARs the answer?","volume":"187","author":"Dawson","year":"2017","journal-title":"Transl. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib80","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36512_bib81","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e36512_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611638","article-title":"Super-treg: toward a new era of adoptive Treg therapy enabled by genetic modifications","volume":"11","author":"Amini","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cei\/uxac078","article-title":"Regulatory T-cell therapy approaches","volume":"211","author":"McCallion","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2024.e36512_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102986","article-title":"Engineered Treg cells: the heir to the throne of immunotherapy","volume":"144","author":"Stucchi","year":"2024","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1759720X17720366","article-title":"Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations","volume":"9","author":"Ajeganova","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36512_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15839","article-title":"Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10067-017-3850-z","article-title":"Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study","volume":"37","author":"Zhu","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36512_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36512_bib90","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36512_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103186","article-title":"Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV\/CMV viremia","volume":"21","author":"Zheng","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.heliyon.2024.e36512_bib92","series-title":"National Library of Medicine (US). 8600 Rockville Pike","year":"2000"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib93","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e36512_bib94a","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib94b","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102645","article-title":"Low-dose Interleukin-2: biology and therapeutic prospects in rheumatoid arthritis","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib95","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4049\/jimmunol.2000455","article-title":"Abatacept promotes regulatory B cell functions, enhancing their ability to reduce the Th1 response in rheumatoid arthritis patients through the production of IL-10 and TGF-\u03b2","volume":"207","author":"Carvajal","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib96","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","article-title":"Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.heliyon.2024.e36512_bib97","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran","volume":"109","author":"Ghoryani","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36512_bib98","first-page":"183","article-title":"The effects of mesenchymal stem cells on the gene expression of TGF-beta and IFN-gamma in patients with rheumatoid arthritis","volume":"22","author":"Rahimi Khorashad","year":"2023","journal-title":"Iran. J. Allergy, Asthma Immunol."},{"key":"10.1016\/j.heliyon.2024.e36512_bib99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/jrms.JRMS_308_20","article-title":"Intravenous injection of autologous bone marrow-derived mesenchymal stem cells on the gene expression and plasma level of CCL5 in refractory rheumatoid arthritis","volume":"25","author":"Alavi","year":"2020","journal-title":"J. Res. Med. Sci."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36512_bib100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/1744666X.2020.1805317","article-title":"Vitamin D: does it help Tregs in active rheumatoid arthritis patients","volume":"16","author":"El-Banna","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36512_bib102","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40259-020-00462-7","article-title":"Administration of CD4+CD25highCD127-FoxP3+ regulatory T cells for relapsing-remitting multiple sclerosis: a phase 1 study","volume":"35","author":"Chwojnicki","year":"2021","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib104","first-page":"157","article-title":"Quality of life in patients with rheumatoid arthritis - a preliminary study","volume":"58","author":"Martinec","year":"2019","journal-title":"Acta Clin. Croat."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36512_bib105","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/art.38715","article-title":"Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway","volume":"66","author":"Cribbs","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"11\u201312","key":"10.1016\/j.heliyon.2024.e36512_bib106","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3727\/096368911X566217","article-title":"The time is crucial for ex vivo expansion of T regulatory cells for therapy","volume":"20","author":"Marek","year":"2011","journal-title":"Cell Transplant."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib107","article-title":"Mild hypothermia provides Treg stability","volume":"7","author":"Marek-Trzonkowska","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113468","article-title":"Mesenchymal stromal cell therapy for patients with rheumatoid arthritis","volume":"423","author":"Harna","year":"2023","journal-title":"Exp. Cell Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib111","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41467-022-28338-0","article-title":"Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity","volume":"13","author":"Piekarska","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36512_bib112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM199607183350303","article-title":"Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients","volume":"335","author":"Kurtzberg","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36512_bib113","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V97.10.2957","article-title":"Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis","volume":"97","author":"Barker","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12683","article-title":"Comparative analysis of mesenchymal stem\/stromal cells derived from human induced pluripotent stem cells and the cognate umbilical cord mesenchymal stem\/stromal cells","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e36512_bib115","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/bloodadvances.2022009619","article-title":"Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS","volume":"7","author":"Gladstone","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36512_bib116","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/sctm.17-0069","article-title":"Umbilical cord blood transplantation: challenges and future directions","volume":"6","author":"Ballen","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36512_bib117","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s12015-022-10351-x","article-title":"A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications","volume":"18","author":"Pakzad","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.heliyon.2024.e36512_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618427","article-title":"Allogeneic CAR cell therapy-more than a pipe dream","volume":"11","author":"Caldwell","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36512_bib119","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/dna.2021.0579","article-title":"How CRISPR\/Cas9 gene editing is revolutionizing T cell research","volume":"41","author":"Johansen","year":"2022","journal-title":"DNA Cell Biol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024125431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024125431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:21:03Z","timestamp":1790544063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024125431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":120,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024125431"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36512","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory T lymphocytes as a treatment method for rheumatoid arthritis \u2013 Superiority of allogeneic to autologous cells","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36512"}}